

Research made to measure.



Please refer to the global disclaimer of this research at the end of document.

公司介绍

Rapid Nutrition PLC是一家天然保健公司,在英国,澳大利亚,美国和欧洲其他地区研究,开发和生产一系列基于科学的健康和保健产品。该公司以Leisa's Secret和 SystemLS的品牌提供基于科学的健康食品补充剂。该公司还以Azurene的名义提供 口服抗病毒治疗产品,以对抗流感和普通感冒。此外,该公司还以DiCED的名义提 供在线健身流媒体服务,目前在大约54个国家/地区提供。截至 2023 年底,植物 基约占总收入的 59.0%,健康和补充产品约占总收入的 41.0%。该公司在英国, 澳大利亚,美国,巴西,法国,意大利,瑞士,沙特阿拉伯,加纳,韩国,牙买 加和加勒比地区分销其产品。澳大利亚子公司(Rapid Nutrition Pty Ltd.)成立于 2001年。英国母公司成立于2012年,总部位于英国伦敦。

风险

我们的投资结论和价格目标面临的风险包括: 1-全球经济急剧下滑, 2-不利的消费 者行为变化, 3-低于预期的市场扩张, 4-流动性和5-对一个市场的高度依赖.




图 1. Rapid Nutrition PLC评级价格量图表*

Source: Industry data and The Zephirin Group, Inc. (ZGI) research *Split adjusted 1:1000

日期	价格	目标	额定值	重要报告	
09-Feb-22	€0.03	€1.00	Buy SR	新兴增长 - 1.00 欧元!	
06-May-22	€0.07			正确的道路 – 1.00 欧元!	
16-Jun-22	€0.03			保持乐观 – 1.00 欧元!	
30-Aug-22	€0.02			一切都是为了九月!	

IMPORTANT GLOBAL DISCLAIMER:

This research is only an opinion and should not be construed as a suggestion. The opinion is provided without any kind of warranty.

Rating System: STRONG BUY — The stock, securities or shares are expected to achieve a total return of 20% or more over the next 12-18 months, or are expected to outperform its industry and the S&P 500. BUY — The stock, securities or shares are expected to achieve a total return of 15% or more over the next 12-18 months, or are expected to outperform its industry peers and the S&P 500. HOLD — The stock, securities or shares are expected to achieve a total return of 10% or less, or are expected to perform in-line with its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 12-18 months. STRONG SELL — The stock, securities or shares are expected to underperform its industry peers and the S&P 500 over the next 6-12 months. SUSPENDED — The stock, securities or shares are temporarily suspended due to market events that made coverage impracticable. Small and mid-sized company stocks involve greater risks than those customarily associated with larger companies.

Risk Rating: LDW RISK (LR) — Return of D-10%; MEDIUM RISK (MR) — Return of D-20%; HIGH RISK (HR) — Return of D-30% and SPECULATIVE RISK (SR) — Return of D-50%. Distribution of Rating: Strong Buy = D (D.0%); Buy = 15 (34.1%); Hold = 11 (25.0%); Sell = 2 (4.5%); Strong Sell = 3 (6.8%), Suspended = 13 (29.5%).

All of the recommendation and views about the securities and companies in this report accurately reflect the personal views of the research analyst named on the cover of this report. In particular the report intended to promote the integrity of research including those designed to ensure the identification and avoidance of conflict of interest.

Note: A securities rating is not a recommendation to BUY, HOLD or SELL securities and may be subject to revision or withdrawal at any time. You acknowledge that the price of securities traded on the Public Regulated Securities Exchanges (i.e., NYSE, NASDAQ, AMEX, Canadian Securities Exchange, Euronext, SIX Swiss Exchange, Hong Kong Stock Exchange, Singapore Stock Exchange) are subject to investment risks, can and does fluctuate, and any individual security may experience upwards or downwards movements, and may even become valueless.

The Zéphirin Group, Inc. ("Z6I") is an independent global equity research company that is incorporated in the State of Delaware on November 2003. The above material has been prepared by Z6I for informational purposes only and should not be construed as an offer to sell or solicitation of an offer to purchase or subscribe for any investment. The information and opinions contained in this report have been compiled or arrived at by Z6I in good faith from sources believed to be reliable, but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. All opinions and estimates contained in this report constitute Z6I's judgment as of the date of this report and are subject to change without notice. Z6I does not provide an analysis of a company's financial position, financial position and all information should be verified with the "mentioned company" investor relations department. Information about publicly listed companies and other investor resources can be found at the Securities & Exchange Commission website www.sec.gov. We are not registered investment advisors, or broker/dealers or members of any financial regulatory bodies, and therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The information contained herein is not to be regarded as advice to make any particular investment. In receiving this material, each recipient represents, warrants and acknowledges that it has taken, or will take, appropriate steps to: obtain such independent legal, tax, accounting and other professional advice as may be appropriate prior to taking any action in relation to any companies form its own independent judgment regarding the risks and rewards associated with any action or inaction relating to any companies mentioned. The information contained herein or indiction relating to any companies mentioned. The Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and as defined in the P

©Copyright 2024 The Zéphirin Group, Inc. ("ZGI"). All rights reserved. This report contains information, text, proprietary information, images, logos and/or other material that is the intellectual property of The Zéphirin Group, Inc. Website: www.zephiringroup.com - www.zephiringroup.中国 - For questions or comments about this report, e-mail us at: info@zephiringroup.com

This report may not be reproduced, distributed or published in electronic, paper or other form for any purpose without the prior written consent of The Zéphirin Group, Inc. Recipients ("YDU") agree to use this research publication solely for their own non-commercial use and benefit, and not for resale or not redistribute or not transfer or recreate the report or any data/information contained in the research publication. Furthermore, recipients may not use any of the trademarks, trade names, service marks, copyrights, or logos of ZGI in any manner which creates the impression that such items belong to and or associated with the recipients. Recipients acknowledge that they have no ownership rights in and or to any such items. No Group Company accepts any liability whatsoever for any direct, indirect or consequential loss arising from any inaccuracy herein or from any use of this report or its contents. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. ZGI accepts no liability whatsoever for the actions of third parties. ZGI makes no representations or warranties whatsoever as to the data and information provided in any third party referenced website and shall have no liability or responsibility arising out of, or in connection with, any such referenced website. Accessing third party portal or website is at your own risk. This publication is made available through Thomson One Analytics www.thomsonnoneim.com First Call research fuert Portal. This publication is available through Thomson Research portal. This publication is also made available through Research portal. This publication regarding this research portal provider. This publication is also made available through ResearchPool www.researchpool.com a research portal provider. This publication is also made available through ResearchPool www.researchpool.com a research portal provider. This publication is also made available through ResearchPool www.researchpool.com a research portal provider.

Canada. Recipients must comply with all applicable laws and regulations of Canada. including any prohibitions on speculative transactions and currency arbitrage trading. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. No action has been taken by ZGI or any affiliate which would permit services of distribution or re-distribution of this document in Canada. Accordingly, the products and services of such entities are not being offered or sold within Canada by means of this document or any other document.

People's Republic of China ("PRC"). Recipients must comply with all applicable laws and regulations of PRC, including any prohibitions on speculative transactions and currency arbitrage trading. No action has been taken by ZGI or any affiliate which would permit services of distribution or re-distribution of this document in the PRC. Accordingly, the products and services of such entities are not being offered or sold within the PRC by means of this document or any other document. This document may not be distributed, re-distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations. Hong Kong (HK). Recipients must comply with all applicable laws and regulations of the Hong Kong Monetary Authority to conduct Type I (dealing in securities), Type 4 (advising on securities) and Type 6 (advising on corporate finance) regulated activities. The contents of this publication have not been reviewed by any regulatory authority in Hong Kong. This report is for distribution only to professional investors within the meaning of Part I of Schedule I to the Securities and Futures Ordinance of Hong Kong (Cap. 57), Laws of HK) and any rules made thereunder and may not be redistributed in whole or in part in Hong Kong to any person. If in doubt about the contents of this publication, you should obtain independent professional advice.

Other Jurisdictions. THIS MATERIAL DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO. The distribution of this research in other jurisdictions may be restricted by law and persons into whose possession this research comes should inform themselves about and observe any such restrictions. By accepting this research' the recipient agrees to be bound by the foregoing instructions.

If this publication has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. ZGI do not accept any Liability as a result of electronic transmission of this publication.

ZGI adheres to the CFA Institute (formerly Association for Investment Management & Research) Research Objective Standards guideline.

This report is intended solely for distribution to the professional investment community within the meaning of Rule ISa-6 of the U.S. Securities and Exchange Commission under the Securities Act of 1934. ZGI or any officers, directors does not hold any equity positions in any company or companies mentioned in this report.

3 THE ZEPHIRIN GROUP, INC.